• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prognostic models in papillary renal cell carcinoma.

作者信息

Attalla Kyrollis, Voss Martin H, Hakimi A Ari

机构信息

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Ann Transl Med. 2020 Nov;8(21):1334. doi: 10.21037/atm-20-3750.

DOI:10.21037/atm-20-3750
PMID:33313079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7723602/
Abstract
摘要

相似文献

1
Prognostic models in papillary renal cell carcinoma.乳头状肾细胞癌的预后模型
Ann Transl Med. 2020 Nov;8(21):1334. doi: 10.21037/atm-20-3750.
2
Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases.乳头状（嗜色性）肾细胞癌：62例的组织形态学特征及传统病理预后参数评估
Am J Surg Pathol. 1997 Jun;21(6):621-35. doi: 10.1097/00000478-199706000-00001.
3
Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.透明细胞和乳头状肾细胞癌的诊断和预后组织标志物。
Cancer Biomark. 2010;7(6):261-8. doi: 10.3233/CBM-2010-0195.
4
Expression of stem-cell markers OCT-4 and CD133: important prognostic factors in papillary renal cell carcinoma.OCT-4 和 CD133 标志物的表达：在乳头状肾细胞癌中重要的预后因素。
Hum Pathol. 2012 Dec;43(12):2109-16. doi: 10.1016/j.humpath.2012.05.006. Epub 2012 Aug 31.
5
Prognostic Factors for Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification: a Study Involving 928 Patients.根据2016年世界卫生组织肾肿瘤分类诊断的肾细胞癌亚型的预后因素：一项涉及928例患者的研究
Pathol Oncol Res. 2017 Jul;23(3):689-698. doi: 10.1007/s12253-016-0179-x. Epub 2016 Dec 28.
6
Mitophagy-associated genes PINK1 and PARK2 are independent prognostic markers of survival in papillary renal cell carcinoma and associated with aggressive tumor behavior.自噬相关基因 PINK1 和 PARK2 是乳头状肾细胞癌患者生存的独立预后标志物，并与侵袭性肿瘤行为相关。
Sci Rep. 2020 Nov 2;10(1):18857. doi: 10.1038/s41598-020-75258-4.
7
Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma.建立并验证用于预测肾乳头状细胞癌患者肾切除术后疾病特异性生存的列线图。
J Urol. 2010 Jul;184(1):53-8. doi: 10.1016/j.juro.2010.03.026. Epub 2010 May 15.
8
Neutrophil Gelatinase Associated Lipocalin is an Independent Predictor of Poor Prognosis in Cases of Papillary Renal Cell Carcinoma.中性粒细胞明胶酶相关脂质运载蛋白是预测肾乳头状细胞癌不良预后的独立指标。
J Urol. 2015 Sep;194(3):647-52. doi: 10.1016/j.juro.2015.04.080. Epub 2015 Apr 25.
9
Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: single-center experience.乳头状组织学分型对侵犯下腔静脉肾细胞癌患者的负面影响：单中心经验。
Int J Urol. 2013 Nov;20(11):1072-7. doi: 10.1111/iju.12123. Epub 2013 Feb 20.
10
A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma.一个五基因标志物可预测乳头状肾细胞癌患者的总生存期。
PLoS One. 2019 Mar 1;14(3):e0211491. doi: 10.1371/journal.pone.0211491. eCollection 2019.

引用本文的文献

1
Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?早期肾细胞癌：谁需要辅助治疗？
Biomedicines. 2025 Feb 21;13(3):543. doi: 10.3390/biomedicines13030543.
2
Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study.替雷利珠单抗联合阿昔替尼新辅助治疗伴下腔静脉瘤栓的非转移性肾细胞癌的疗效和安全性：一项回顾性研究
Sci Rep. 2025 Jan 17;15(1):2248. doi: 10.1038/s41598-025-86712-6.
3
A novel nomogram and risk classification system predicting the overall survival of patients with papillary renal cell carcinoma after nephrectomy: A population-based study.一种基于人群的研究：预测肾细胞癌患者肾切除术后总生存的新型列线图和风险分类系统。
Front Public Health. 2022 Oct 5;10:989566. doi: 10.3389/fpubh.2022.989566. eCollection 2022.

本文引用的文献

1
The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.基于 ASSURE 前瞻性临床试验队列的非转移性乳头状肾细胞癌术后疾病复发预测的 VENUSS 预后模型：开发与评估。
BMC Med. 2019 Oct 3;17(1):182. doi: 10.1186/s12916-019-1419-1.
2
Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?具有肉瘤样特征的肾细胞癌：终于有新的治疗希望了？
Cancers (Basel). 2019 Mar 25;11(3):422. doi: 10.3390/cancers11030422.
3
Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers.精准医学时代的肾细胞癌：从分子病理学到基于组织的生物标志物
J Clin Oncol. 2018 Oct 29;36(36):JCO2018792259. doi: 10.1200/JCO.2018.79.2259.
4
Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis.肿瘤坏死作为肾细胞癌患者临床结局的预后变量：系统评价和荟萃分析。
BMC Cancer. 2018 Sep 3;18(1):870. doi: 10.1186/s12885-018-4773-z.
5
Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.高危非透明细胞肾细胞癌患者肾切除术后复发模式及对术后监测的影响：ECOG-ACRIN E2805 期试验的亚组分析。
J Urol. 2019 Jan;201(1):62-68. doi: 10.1016/j.juro.2018.08.041.
6
Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.预测肾细胞癌手术后的肿瘤学结果。
Eur Urol. 2018 May;73(5):772-780. doi: 10.1016/j.eururo.2018.01.005. Epub 2018 Feb 3.
7
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.一种用于轻松预测肾细胞癌预后的新模型的验证：应用于ASSURE试验人群的GRANT评分
Ann Oncol. 2017 Nov 1;28(11):2747-2753. doi: 10.1093/annonc/mdx492.
8
Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.在非转移性疾病中，乳头状肾细胞癌与透明细胞肾细胞癌的预后差异显著。
PLoS One. 2017 Sep 21;12(9):e0184173. doi: 10.1371/journal.pone.0184173. eCollection 2017.
9
Characterizing the outcomes of metastatic papillary renal cell carcinoma.转移性乳头状肾细胞癌的预后特征分析。
Cancer Med. 2017 May;6(5):902-909. doi: 10.1002/cam4.1048. Epub 2017 Apr 16.
10
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.舒尼替尼或索拉非尼辅助治疗高危、非转移性肾细胞癌（ECOG-ACRIN E2805）：一项双盲、安慰剂对照、随机3期试验。
Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9.